Podcasts about AAV

Craig reacts to Diana Russini's latest reporting on the Terry McLaurin contract negotiations. Russini joined BMitch and Finlay and clarified that McLaurin is not asking for DK Metcalf-level AAV. Craig weighs in on her comments—especially her line about “who's got the stomach for it” in these talks. Plus, Craig and Anthony go back and forth on whether the Commanders can beat the Giants in Week 1 with—or without—Terry McLaurin.

Lucas Raymond has been recognized as one of the best contracts in the NHL, which begs the question: just how good is the Detroit Red Wings core's cap structure? Tune in as we discuss Steve Yzerman's position as he navigates a rising salary cap and what he has in Dylan Larkin, Lucas Raymond, and Moritz Seider long term, and how that affect his ability to attract future superstars or any free agent talent, extend Alex DeBrincat and Patrick Kane, sign Marco Kasper (Michigan goal-scorer), Nate Danielson, Axel Sandin Pellikka, and others after their ELCs, and more (4:05). Next, we go over Simon Edvinsson's next contract, when the best time for Steve Yzerman to sign him would be, what his AAV will look like next to Moritz Seider, how he fared with Albert Johansson, & more (33:35) before we take your questions and comments in our Overtime segment (56:10) - enjoy! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! Go to TempoMeals.com/WINGEDWHEEL  for 60% off your first box! #ad Go to KoffeeKult.com and use code WWP for 15% off your order! #ad Support the Jamie Daniels Foundation through Wings Money on the Board: https://www.wingedwheelpodcast.com/wingsmotb Best Contracts Article: https://www.nytimes.com/athletic/6513956/2025/07/29/nhl-best-contracts-2025-jack-hughes-brandon-hagel/

Howie and Harlan are joined by public health communicator Katelyn Jetelina for updates on COVID-19 and other issues, and to discuss how her emails to students and colleagues in the early days of the pandemic turned into a platform with global reach. Harlan looks at how AI is being used on both sides of the battle between providers and insurers over claims; Howie reports on a setback with a promising gene therapy for Duchenne muscular dystrophy. Links: Insurance Claims, AI, and Wearables “Elevance Health Reports Second Quarter 2025 Results” “Elevance lowers profit outlook, warns things will get worse for health insurers ““Blue KC wrongfully denied medical diagnoses, hospital alleges in AI-driven claims lawsuit” “Oscar Health cuts full-year guidance, estimates 2025 loss as ACA marketplace stumbles” Whoop “WHOOP Delivers Innovative Blood Pressure Insights for a Deeper Look at Your Well-Being” “Introducing Heart Screener: A smarter way to stay connected to your heart health” “Whoop says FDA is ‘overstepping its authority' with warning about blood pressure feature” FDA: WARNING LETTER, WHOOP, Inc. “RFK Jr. wants everyone to use wearables. What are the benefits, risks?” “Apple to Sell Watches With Blood-Oxygen Feature Disabled After Legal Setback” Your Local Epidemiologist Your Local Epidemiologist “Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism” “Popular epidemiologist lays out future path of public health communication” Yale School of Public Health: PopHIVE Katelyn Jetelina: “NIH: The quiet engine of science is being dismantled” Katelyn Jetelina: “Covid-19 in pockets, sugar cane isn't better, ticks march on, rescission cuts (vs. everything else), bright spots, and more” Mayo Clinic: Norovirus infection Katelyn Jetelina: “The show must go on...” Katelyn Jetelina: “Harassment against scientists is out of control” Katelyn Jetelina: “Medicaid cuts: The how and why” CDC: H5 Bird Flu: Current Situatio CDC: Current Epidemic Trends (Based on Rt) for States” CDC: Measles Cases and Outbreaks Treating Duchenne Muscular Dystrophy Cleveland Clinic: Duchenne Muscular Dystrophy (DMD) “FDA approves Sarepta's Duchenne gene therapy for nearly all patients” “AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial” “Patient dies in Sarepta gene therapy trial, adding to safety concerns” “FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths” “In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy” “Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

On this week's Inside Startup Investing, Dr. Nicole Paulk—founder & CEO of Siren Biotechnology—details her AAV gene-therapy “FedEx truck” that can deliver anti-tumor cytokines directly to brain cancers. Early animal data show 86 % complete responses; the FDA has signaled a fast-track path for Siren's first-in-human trial set for 2026. With analog comps like Keytruda earning $30 B a year, Siren's upside—and impact—could be enormous.Highlights include...Why viruses? AAV viruses don't cause disease in humans yet efficiently deliver genetic payloads; Siren re-engineers them to express anti-tumor cytokines.Twin “firsts.” Siren pursues the first AAV-based cancer therapy and the first single virus platform scalable to hundreds of indications.Animal data. >500 mouse models show 86 % complete responses; large-animal pig study indicates strong safety with real-world neurosurgical delivery.Clinical plan. Combined Phase 1/2 trial in adults with recurrent high-grade gliomas targeted for 2026 with potential for rare-disease (orphan) fast-track.Market context. Current SOC for brain tumors is largely ineffective; analogous immunotherapies like Keytruda generate ~$30 B annually.

Howie and Harlan are joined by public health communicator Katelyn Jetelina for updates on COVID-19 and other issues, and to discuss how her emails to students and colleagues in the early days of the pandemic turned into a platform with global reach. Harlan looks at how AI is being used on both sides of the battle between providers and insurers over claims; Howie reports on a setback with a promising gene therapy for Duchenne muscular dystrophy. Links: Insurance Claims, AI, and Wearables “Elevance Health Reports Second Quarter 2025 Results” “Elevance lowers profit outlook, warns things will get worse for health insurers ““Blue KC wrongfully denied medical diagnoses, hospital alleges in AI-driven claims lawsuit” “Oscar Health cuts full-year guidance, estimates 2025 loss as ACA marketplace stumbles” Whoop “WHOOP Delivers Innovative Blood Pressure Insights for a Deeper Look at Your Well-Being” “Introducing Heart Screener: A smarter way to stay connected to your heart health” “Whoop says FDA is ‘overstepping its authority' with warning about blood pressure feature” FDA: WARNING LETTER, WHOOP, Inc. “RFK Jr. wants everyone to use wearables. What are the benefits, risks?” “Apple to Sell Watches With Blood-Oxygen Feature Disabled After Legal Setback” Your Local Epidemiologist Your Local Epidemiologist “Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism” “Popular epidemiologist lays out future path of public health communication” Yale School of Public Health: PopHIVE Katelyn Jetelina: “NIH: The quiet engine of science is being dismantled” Katelyn Jetelina: “Covid-19 in pockets, sugar cane isn't better, ticks march on, rescission cuts (vs. everything else), bright spots, and more” Mayo Clinic: Norovirus infection Katelyn Jetelina: “The show must go on...” Katelyn Jetelina: “Harassment against scientists is out of control” Katelyn Jetelina: “Medicaid cuts: The how and why” CDC: H5 Bird Flu: Current Situatio CDC: Current Epidemic Trends (Based on Rt) for States” CDC: Measles Cases and Outbreaks Treating Duchenne Muscular Dystrophy Cleveland Clinic: Duchenne Muscular Dystrophy (DMD) “FDA approves Sarepta's Duchenne gene therapy for nearly all patients” “AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial” “Patient dies in Sarepta gene therapy trial, adding to safety concerns” “FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths” “In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy” “Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Big Show + with GVP and Aazam Ali Nanji is on demand! In this hour, Zack Warden joins the show to discuss the importance of the trade deadline for the Toronto Blue Jays, thoughts on the series against the Yankees, and more.(27:24) GVP and Aazam discuss the Connor Zary contract situation with the team and player apart on AAV. Plus more on where he fits long-term with the Flames.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Chris Russell, with some insight from AMAC, analyzes whether AAV (average annual value), contract length, or guarantees are the main factors delaying Terry McLaurin's contract. They reference various events and audio clips from the negotiation process to support their conclusions

The second half of the season starts today for the Mariners as they take on the Astros for a 3-game series. In the past few years, the Mariners have not had success out the gate after the All-Star break. Bump & Curtis break down what the Mariners need to do to avoid a slow start to the second half. // Headline Rewrites: Nick Emmanwori and the Seahawks reached an agreement on a fully guaranteed rookie contract. Damian Lillard and the Trail Blazers are reuniting after two seasons spent apart in Milwaukee. TJ Watt and the Steelers agreed to a 3-year extension with an AAV of $41 million, making him the new highest paid defensive player. // With Nick Emmanwori and Elijah Arroyo finally signing their rookie contracts, what does this tell us about the Seahawks and how they are operating? The guys give us their takes on what this new style of wanting fully guaranteed money for rookie contracts means for this organization and the NFL. // During the All-Star break, Jerry Dipoto caught up some of the media to talk about the trade deadline. He feels like we have a fairly complete roster and would be looking for a move that would be meaningful. He is aware that there some rental players that would fit in this clubhouse but nothing is certain. How are we feeling about these statements? 

The Seattle Times’ Bob Condotta joins Bump & Curtis to give us a preview of this Seahawks team prior to the start of next week’s training camp. He also gives us his reaction to both Nick Emmanwori and Elijah Arroyo finally singing their rookie contracts. Could we see any contract extensions get done as we are less than a week away from training camp? // Headline Rewrites: Nick Emmanwori and the Seahawks reached an agreement on a fully guaranteed rookie contract. Damian Lillard and the Trail Blazers are reuniting after two seasons spent apart in Milwaukee. TJ Watt and the Steelers agreed to a 3-year extension with an AAV of $41 million, making him the new highest paid defensive player. // NFL Headlines: Lloyd Howell has resigned as NFLPA Executive Director after it was found out that he had a part-time role with a private equity firm that was approved to buy minority stakes in NFL Teams. He also expensed two strip club visits to the NFLPA expense card. Michah Parsons gave an update on his contract talks with the cowboys to the Undertaker. // In order for the Seahawks to be a playoff team this season, who needs to outperform expectations? Curtis thinks that if Cooper Kupp can exceed expectations it would help out Sam Darnold and allow this offense to be dominant. Bump says Kenneth Walker is the one player that needs to exceed expectations for this offense to find success. 

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ralf Schmid, Ph.D., Associate Director of Preclinical Research at Novartis Biomedical Research, about the evolving use of large animal models in gene therapy development. Dr. Schmid discusses the current reliance on non-human primates (NHPs), their growing logistical and ethical challenges, and the emerging interest in alternatives like genetically engineered pigs and sheep. He outlines key considerations around safety, biodistribution, and immunogenicity that still necessitate large-animal testin —particularly for CNS-targeted AAV therapies — and emphasizes the need for thoughtful study design, responsible sourcing, and diversification in model systems. Dr. Schmid also previews his participation in the upcoming Next Generation Gene Therapy Vectors Summit and reflects on the future of preclinical safety testing in a landscape aiming to balance innovation, rigor, and compassion.Subscribe to the podcast!Apple | Spotify | YouTube

This episode is the third in a series hosted by Molecular Therapy Editor-in-Chief Joseph Glorioso, PhD, that will cover comprehensive reviews of critical developments in the field of gene and cell therapy over the past 25 years. In this episode, Dr. Glorioso will discuss the reviews, “Current trends in gene therapy to treat inherited disorders of the brain,” with author Beverly Davidson, PhD, The Children’s Hospital of Philadelphia, and “The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy,” with author Jeff Chamberlain, PhD, University of Washington School of Medicine. If you enjoy this deep dive into research that is critical to the field, check out two more ASGCT events happening this fall: Advancing Cell and Gene Therapies for Cancer and Breakthroughs in Targeted In Vivo Gene Editing. During these events – in October and November, respectively – you’ll be able to hear directly from researchers about their own work related to these topics, or you can submit your own abstract for possible presentation. We hope to see you there! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP at Astellas Gene Therapies, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds.

The guys are forced to call an audible! Cam & Jim had planned to revisit some of the best "lost" takes from Free-For-All Friday... but that's going to have to wait. First, they sit down with Winnipeg Jets forward Morgan Barron, who just signed a new two-year deal with an AAV of $1.85 million. They ask Barron about his new contract, expectations for the season, and how he sees his role evolving with the Jets. Then, it's back to the inbox -- your best texts and social media takes from Friday, including more talk on the NCAA vs. the CHL, the changing development path of Canadian hockey players, and Jonathan Toews' goal total. It's all coming up on today's episode of Jets @ Noon. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Philadelphia Flyers were able to re-sign RFA Defenseman Cam York to a 5 year extension on Monday. The deal will have an AAV of 5.15 Million a year during that time. Also on tap for Tuesday the boys will be breaking down the offseason as a whole. They will review the Free Agents signed, trades made, picks from the draft and give their overall grades on the offseason. Be sure to drop your comments in the chat and be a part of the show! Make sure you hit that like and subscribe wherever you watch or listen to Flyers Talk A2D!Like, Comment, and Subscribe for more!/ a2dradio  Facebook:   / a2dradio  Instagram:   / a2dradio  X:   / a2dradio  Website: http://a2dradio.com/_______________We thank you for your support!Specialized Physical Therapy:https://specializedphysicaltherapy.com/Boaggiosbread: https://boaggiosbread.com/Alan Foy:https://www.exprealty.com/

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development. Subscribe to the podcast!Apple | Spotify | YouTube

(00:00) Joe Murray and Matt McCarthy filling in for Toucher and Hardy today. Started off the day very strong talking about catholic school, the movie Departed and Marky Mark and the Funky Bunch. (22:09) WHAT HAPPENED LAST NIGHT: Bruins signed Tanner Jeannot for five years for 3.4 million AAV. Joe and Matt aren’t too thrilled about the signing to say the least. The Red Sox were winning 2-1 at the top of the 4th against the Reds last night until it got suspended due to the lightning storm. How delusional is the Red Sox Management? CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

Free agency is in full swing, and we're back with another offseason edition of Oilersnation Everyday to break down all the action from Day 1 and beyond.The Edmonton Oilers made a notable addition on July 1st, signing Andrew Mangiapane to a 2-year deal worth $3.6 million AAV, adding another versatile piece to their top nine. While the Oilers lost Connor Brown and Corey Perry to the open market, they also added Matt Tomkins and Riley Stillman on two-way contracts to strengthen their depth chart.We'll recap everything the Oilers did on Day 1, explore what their next moves might be, and evaluate how their offseason is shaping up so far. Could they still target a bargain-bin forward or veteran defenseman? Is a trade still on the table?We'll also go around the league to talk about the biggest signings from Day 1 of free agency, deliver our One Big Take, ask The Giant Question, and close out the show with some picks from Bet365.Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

Free agency day means a fresh episode of Oilersnation Radio is ready to massage your earholes and bring you up to date on everything going on with the Edmonton Oilers. On today's podcast, the fellas discussed the Evan Bouchard extension, the NHL Draft, Kasperi Kapanen, and much more.We kicked off the Monday episode of ONR with a delicious debate about where everyone is at with Evan Bouchard's four-year, $10.5m AAV contract, and whether it's not more of a problem that Bowman wasn't able to lock in the max term. We also discussed the Oilers re-signing both Kasperi Kapanen and Noah Philp before they were able to reach free agency, likely with the plan of having both of these players start on the opening day roster. Chances are, the Oilers are going to be tight for cap space when October rolls around, and they'll need cheaper deals on the books to fill holes in the roster.With plenty of time left to go until the deals slow down, the boys walked through some of our former friends who signed elsewhere on Tuesday, including Corey Perry's new deal in Los Angeles and Connor Brown's contract in New Jersey. While we all expected a quieter day in Edmonton given the team's lack of cap space, that doesn't make it any easier to see contributing roster players sign for big smoke in other markets. Regardless, the deals signed in the early hours on July 1st don't mean the Oilers are anywhere close to done, but that didn't stop many Oilers fans from being disappointed anyway.Regardless of what the Oilers have done or haven't done yet, there's little doubt that teams are spending big money on free agents with the salary cap expected to fly up over the next handful of years. In fact, one could make the argument that the Oilers could be better off avoiding some of these overpriced free agents, especially with the dollars that some mid-tier UFAs are signing on extended deals. Is that coping? Potentially yes. Hosted on Acast. See acast.com/privacy for more information.

The Mitch Marner saga has come to an end. The Golden Knights hand Toronto Maple Leafs have worked out a sign and trade to send Marner to Vegas on a brand new 8 year, $12m AAV contract, with Nic Roy going back the other way to Toronto. Subscribe to The Jesse Blake Sports Report YouTube Channel: https://www.youtube.com/@JesseBlakeTV?sub_confirmation=1Follow Jesse on Twitter at @JesseBlakeFollow Jesse on Instagram @Jesse.BlakeVisit https://sdpn.ca for more.Join us on Discord: https://discord.com/invite/MtTmw9rrz7For general inquiries email: info@sdpn.caReach out to https://www.sdpn.ca/sales to connect with our sales team and discuss the opportunity to integrate your brand within our content!Join SDP VIP:YouTube: https://www.youtube.com/channel/UC0a0z05HiddEn7k6OGnDprg/joinApple Podcasts: https://apple.co/thestevedanglepodcastAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Free agency day means a fresh episode of Oilersnation Radio is ready to massage your earholes and bring you up to date on everything going on with the Edmonton Oilers. On today's podcast, the fellas discussed the Evan Bouchard extension, the NHL Draft, Kasperi Kapanen, and much more.We kicked off the Monday episode of ONR with a delicious debate about where everyone is at with Evan Bouchard's four-year, $10.5m AAV contract, and whether it's not more of a problem that Bowman wasn't able to lock in the max term. We also discussed the Oilers re-signing both Kasperi Kapanen and Noah Philp before they were able to reach free agency, likely with the plan of having both of these players start on the opening day roster. Chances are, the Oilers are going to be tight for cap space when October rolls around, and they'll need cheaper deals on the books to fill holes in the roster.With plenty of time left to go until the deals slow down, the boys walked through some of our former friends who signed elsewhere on Tuesday, including Corey Perry's new deal in Los Angeles and Connor Brown's contract in New Jersey. While we all expected a quieter day in Edmonton given the team's lack of cap space, that doesn't make it any easier to see contributing roster players sign for big smoke in other markets. Regardless, the deals signed in the early hours on July 1st don't mean the Oilers are anywhere close to done, but that didn't stop many Oilers fans from being disappointed anyway.Regardless of what the Oilers have done or haven't done yet, there's little doubt that teams are spending big money on free agents with the salary cap expected to fly up over the next handful of years. In fact, one could make the argument that the Oilers could be better off avoiding some of these overpriced free agents, especially with the dollars that some mid-tier UFAs are signing on extended deals. Is that coping? Potentially yes. Hosted on Acast. See acast.com/privacy for more information.

Friday afternoon means a fresh episode of Oilersnation Radio is ready to be enjoyed. On today's podcast, the fellas discussed what's to come for the Oilers, Trent Frederic's new contract, the NHL Draft, free agency, and much more.We kicked off the Friday episode of Oilersnation Radio with a delicious debate about the Trent Frederic contract extension and what everyone's first thoughts are on the deal. From the max-term contract to the $3.85m AAV to the no-trade protection of various types throughout the life of the contract, the boys had plenty to say about our newest long-term friend.Changing gears, we explored some of the latest news and rumours surrounding the Oilers as they head into the offseason, and assessed the realism of these ideas given the team's limited cap space. Naturally, we all have high hopes that Stan Bowman will be able to make some magic happen, but we all know that many of the hopes and dreams we all have for the franchise. Finally, we wrapped up the Friday episode of ONR with another round of Ask the Idiots, betting talk for our friends at bet365, and Hot and Cold Performers to look back on the week. With the NHL Draft and free agency on deck, the guys spent the bulk of the Friday episode talking about what to expect over the next week, and how the Oilers could look like a much different hockey team by this time next week. Hosted on Acast. See acast.com/privacy for more information.

John Tavares is sticking around! He and the Toronto Maple Leafs have reached a 4 year contractr extension worth $4.38m AAV.Subscribe to The Jesse Blake Sports Report YouTube Channel: https://www.youtube.com/@JesseBlakeTV?sub_confirmation=1Follow Jesse on Twitter at @JesseBlakeFollow Jesse on Instagram @Jesse.BlakeVisit https://sdpn.ca for more.Join us on Discord: https://discord.com/invite/MtTmw9rrz7For general inquiries email: info@sdpn.caReach out to https://www.sdpn.ca/sales to connect with our sales team and discuss the opportunity to integrate your brand within our content!Join SDP VIP:YouTube: https://www.youtube.com/channel/UC0a0z05HiddEn7k6OGnDprg/joinApple Podcasts: https://apple.co/thestevedanglepodcastAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

It's another offseason edition of Oilersnation Everyday and we've got breaking news to kick things off! This morning, the Edmonton Oilers officially signed Trent Frederic to an 8-year extension with an AAV of $3.85 million per season. We'll break down the contract details, discuss whether the term and value make sense for Edmonton's long-term plans, and look at what kind of role Frederic could play over the life of the deal.With the Oilers still tight to the cap, what comes next? Could Viktor Arvidsson be the next piece to move ahead of free agency to free up more space? We'll explore that possibility, and look at how the Oilers might be positioning themselves for further additions or extensions — especially with Evan Bouchard and Connor McDavid's situations looming large.We'll also be joined by former NHL defenseman Jason Demers, who will share his thoughts on the Frederic deal, Edmonton's cap strategy, and what else he thinks Ken Holland and the Oilers front office could be cooking up this summer.All that and more on today's show!Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

Friday afternoon means a fresh episode of Oilersnation Radio is ready to be enjoyed. On today's podcast, the fellas discussed what's to come for the Oilers, Trent Frederic's new contract, the NHL Draft, free agency, and much more.We kicked off the Friday episode of Oilersnation Radio with a delicious debate about the Trent Frederic contract extension and what everyone's first thoughts are on the deal. From the max-term contract to the $3.85m AAV to the no-trade protection of various types throughout the life of the contract, the boys had plenty to say about our newest long-term friend.Changing gears, we explored some of the latest news and rumours surrounding the Oilers as they head into the offseason, and assessed the realism of these ideas given the team's limited cap space. Naturally, we all have high hopes that Stan Bowman will be able to make some magic happen, but we all know that many of the hopes and dreams we all have for the franchise. Finally, we wrapped up the Friday episode of ONR with another round of Ask the Idiots, betting talk for our friends at bet365, and Hot and Cold Performers to look back on the week. With the NHL Draft and free agency on deck, the guys spent the bulk of the Friday episode talking about what to expect over the next week, and how the Oilers could look like a much different hockey team by this time next week. Hosted on Acast. See acast.com/privacy for more information.

In a truly stunning, out-of-left-field event, the Giants traded for slugger Rafael Devers. It really did come out of nowhere, but it's genesis was the discontent that was brewing in Boston after Devers was not being treated like a franchise player, being promised third base, only to have Alex Bregman usurp it. The Giants gave up relatively little as a price for securing Devers for the next 8 1/2 years. This was not a rental, and often 2 month rentals end up costing teams a LOT more than what the Giants gave up. All told, the Giants traded away Kyle Harrison, Jordan Hicks, and two prospects. Even the AAV for Devers is under what the market would bear now and certainly what it will bear in several years. Devers is in the prime of his career at age 28. Buster Posey made this happen, and he is the man right now. Eric, Willie, and Chad discuss this blockbuster and can't find a comp to it in recent Giants history. We are all excited, but if the Giants would just actually perform on the field. After briefly tying the Dodgers for first place in the NL West over the weekend, they have lost 4 in a row and 5 of 6 overall. Let's hope they snap out of it with the help of their new shiny star.@torturecastfacebook.com/torturecasttorturecast.com

One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.

The Stanley Cup Final loss still stings, but the focus has now fully shifted to the future. On today's edition of Oilersnation Everyday, Tyler, Liam, and Producer Bordzy dissect what's shaping up to be a pivotal offseason for the Edmonton Oilers.Will Connor McDavid commit long-term and sign an extension this summer? Could the team explore moving on from Darnell Nurse and his hefty cap hit after another frustrating playoff run? These are just a few of the major questions we'll try to answer on the show.We'll also project what next season's lineup could look like and explore some possible offseason moves — especially in net. Is Stuart Skinner still the guy? And if so, who could the Oilers bring in to form a more reliable tandem?Plus, we'll break down the news of the weel: Will Trent Frederic stay in Edmonton? The Oilers and Frederic have been linked to an 8-year extension with an AAV of $4 million per season. We'll give our thoughts on the potential deal, what it could mean for the team's cap structure moving forward, and why management feels Frederic was a long-term fit for this core.We're also joined by What Chaos! host DJ Bean to get his perspective on the Oilers' playoff run, the sting of back-to-back Stanley Cup Final losses, and what Edmonton needs to prioritize if they want to finally get over the hump next season.It's a loaded offseason edition of the show — let's get into it.Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

Ben and Brent continue the hockey talk into the final hour on Monday. The hosts welcome on Daily Faceoff insider, Frank Seravalli, to break down the Stanley Cup Final. He debates if Edmonton's goaltending situation is one of the main reasons they're a game away from losing the championship in consecutive years. They then look ahead to the upcoming free agent market and parse through some of the top names set to hit the market. They discuss if Brad Marchand could get a higher AAV than Sam Bennett and what Mitch Marner will be seeking. The morning duo then check in with Blue Jays Central analyst, Madison Shipman (28:55), to talk about Toronto's MLB team and how they can reset returning to Rogers Centre this week after getting swept to close out their road trip. The trio discuss Vladimir Guerrero Jr.'s tendency to walk over hitting for power, as well as what has made Alejandro Kirk so consistent and productive this season.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

BSR has published a new set of management recommendations for ANCA-associated vasculitis (AAV), serving as an update to our AAV guideline last published in 2017.Find out more via our blog. Join guideline working group Chair, Lorraine Harper, and group members Rosemary Hollick, Harold Wilson-Morkeh, Georgina Ducker and expert by experience member, Zoi Anastasa, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since the 2017 guideline was published. Sign up for the BSR educational webinars to accompany the recommendations here: https://www.rheumatology.org.uk/events-learning/webinars/updated-recommendations-for-managing-anca-associated-vasculitis Read the full guideline and download the summary pdf here. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In honor of Molecular Therapy’s 25th anniversary, this episode is the second in a series hosted by Dr. Joseph Glorioso, Editor-in-Chief of Molecular Therapy, that will cover comprehensive reviews of critical developments in the field of gene and cell therapy over the past 25 years. In this episode, Dr. Glorioso will discuss the reviews, AAV vector development, back to the future, with author Sheila Mikhail; M34, Inc.; and The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy; with author Dr. Mark Kay, Stanford University. If you enjoy this deep dive into research that is critical to the field, check out two more ASGCT events happening this fall: Advancing Cell and Gene Therapies for Cancer and Breakthroughs in Targeted In Vivo Gene Editing. During these events – in October and November, respectively – you’ll be able to hear directly from researchers about their own work related to these topics, or you can submit your own abstract for possible presentation. We hope to see you there! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

The Colorado Avalanche have locked in their 2C with Brock Nelson signing a three year $7.5 million AAV contract with the team. The First piece to the Avs postseason puzzle is set, what does mean for the Avs and what comes next? Intro - 0:00First reactions - 1:00Skating Data - 6:25High danger scoring - 20:35A bit much? - 31:30Still some work to be done, but..- 38:00Where's the snarl? - 58:15Wrapping up - 1:02:00 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events ALL THINGS DNVR: https://linktr.ee/dnvrsports MERCH: https://store.allcitynetwork.com/collections/dnvr-locker SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Toyota: Visit Your Front Range Toyota Stores at a location near you - Toyota is the official vehicle of DNVR. Toyota - Let's Go Places! First Bank: So, if you're ready for better banking and the chance to earn a little extra, head to efirstbank.com/bonus. Certain restrictions and requirements apply. Member FDIC. Hall of Fame App: Get a 7-Day Free Trial + 50% Off your first month with code DNVR. Just download the HOF app on iOS and Android or visit www.hofbets.com, enter code DNVR, and you're all set. #ad Monarch Money: Use Monarch Money to get control of your overall finances with 50% off your first year at https://www.monarchmoney.com/dnvr bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLERUCHealth: Learn more about Living Like There's A Tomorrow at https://www.uchealth.org/tomorrow/?utm_source=DNVR&utm_medium=Audio&utm_campaign=Brand_LLTIAT_Null_JFMFY25_AW_Null Coors Light:  Delivery on Instacart at https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Gametime: Download the app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Shady Rays: Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. Get 10 FREE meals at https://hellofresh.com/freeavalanche. Applied across 7 boxes, new subscribers only, varies by plan. https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLER When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.#coloradoavalanche #hockey #hockeypodcast

We have another busy day to get through all the Philadelphia Flyers news and rumors floating around.First, Noah Cates is Danny Briere's most recent piece of business, signing an extension today for 4 years with a $4 million AAV.Also, Roger McQueen has said he's 10/10 healthy following a misdiagnosis of his back injury. If the 6-5 center prospect is truly 100%, can the Flyers afford to pass on him if available at #6?There's also Charlie's first Mock Draft, a Brent Flahr Q&A in the Inquirer, and more!

In this episode of the BroadEye Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes welcome Prof. Michel Michaelides, one of the most active clinical researchers in ophthalmology today. Prof. Michaelides leads a large inherited retinal disease clinic—seeing 30–40 children and adults each week—and splits her time between patient care, advanced imaging research, and steering more than ten ongoing clinical trials.   Why This Matters Inherited retinal diseases affect hundreds of thousands worldwide, and for most there is still no approved treatment. Over the past two years, we've seen multiple Phase 1/2 gene-therapy trials move into registrational studies, alongside novel antioxidant approaches and AI-driven biomarkers. Today's conversation cuts through the jargon to give you a clear picture of where the field stands—and where it's headed.   Key Takeaways Beyond RPE65: While Luxturna paved the way, newer AAV-based therapies for X-linked RP (RPGR) and other targets are now in Phase 2 and Phase 3 trials, with early data showing promising safety and efficacy. Imaging & Function: Prof. Michaelides is pioneering next-generation retinal imaging devices and novel functional assays to capture meaningful changes in vision—critical for shortening trial timelines. Antioxidant Strategies: High-dose N-acetylcysteine trials are under way, offering a non-viral approach to slow photoreceptor degeneration across multiple genetic subtypes. AI in Stratification: Machine-learning algorithms on retinal scans can help predict progression rate and identify the best candidates for specific therapies, improving both trial design and patient outcomes. Balancing Dose & Safety: Finding the sweet spot between transgene expression and immune activation remains a core challenge—Prof. Michaelides shares lessons learned from dose-escalation cohorts. Phase 3 & Beyond: With over a hundred patients enrolled in pivotal studies, we're closing in on potential approvals—but long-term follow-up and real-world evidence will determine ultimate impact.   About the Guest Prof. Michelle Michaelides is a clinician-scientist specializing in inherited retinal diseases. She leads dedicated adult and pediatric IRD clinics, oversees the development of advanced imaging and functional biomarkers, and serves as principal investigator on over ten clinical trials spanning gene therapies, antioxidant agents, and AI-guided stratification tools. Prof. Michaelides regularly lectures at international conferences and collaborates with industry and academic partners to accelerate the translation of research into real-world treatments.

In this latest episode of the BroadEye podcast, hosts Shawn Maloney and Dr. Bruno Fernandes sit down with Dr. Arshad M. Khanani, MD, MA, FASRS, a pioneer in vitreoretinal gene-therapy trials and Managing Partner at Sierra Eye Associates. Dr. Khanani shares front-line insights into how genetic medicines are reshaping treatment for inherited and degenerative retinal diseases, highlighting both the promise and the practical challenges of bringing one-time therapies to patients.   Why Gene Therapy Matters Today Recent years have seen the first US approvals of in-vivo retinal gene therapies, beginning with voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy in December 2017. These one-off treatments offer durable vision improvements where none existed before, but they also raise questions of long-term safety, vector delivery, and equitable access.   Dr. Khanani's Journey With over a decade leading surgical trials in sustained-delivery and viral-vector therapies, Dr. Khanani has overseen early human work on next-generation agents—including subretinal injections of AAV vectors and novel capsid designs. He describes lessons learned from Phase 1 safety studies through global registrational trials, emphasizing iterative “vector evolution” to boost efficacy and minimize inflammation.   Key Takeaways Vector Optimization: Directed-evolution platforms are accelerating discovery of capsids that target photoreceptors more precisely, reducing off-target toxicity. Durability vs. Dose: Striking the right balance between transgene expression and immune activation remains central—higher doses don't always equal better outcomes. Regulatory Pathways: While Luxturna set a precedent, streamlined FDA and EMA guidance on trial endpoints and real-world evidence will shape the next wave of approvals. Cost & Access: Innovative payment models (e.g., outcomes-based installment plans) are emerging to address the multi-hundred-thousand-dollar price tags of these therapies.   About the Guest Dr. Arshad M. Khanani, MD, MA, FASRS, is a vitreoretinal surgeon, researcher, and Managing Partner at Sierra Eye Associates in Reno, Nevada. He holds dual degrees in medicine and medical humanities from the University of Nevada, Reno, and is a fellow of the American Society of Retina Specialists. Dr. Khanani has authored over 100 peer-reviewed articles on retinal disease and served as principal investigator on more than 30 clinical trials of gene and cell therapies for inherited and age-related retinal disorders. He also lectures internationally on surgical innovation, vector design, and the economics of advanced ocular treatments.

In a major scientific breakthrough, researchers from 29 institutions across North America—led by the Allen Institute—have developed over 1,000 new genetic tools called enhancer AAV vectors to precisely target specific brain cells. Guest: Dr. Bosiljka Tasic - Director of Molecular Genetics at the Allen Institute for Brain Science Learn more about your ad choices. Visit megaphone.fm/adchoices

Sunday May 18, 2025. Week 21   Show notes on the site: https://curesyngap1.org/podcasts/syngap10/    CAMP4 Press Release https://investors.camp4tx.com/news-releases/news-release-details/camp4-presents-translational-data-syngap1-related-disorders Dr. Yuri at WODC: https://www.youtube.com/watch?v=oNwgo7TmrVo Presentation at ASGCT: https://investors.camp4tx.com/news-events/presentations GETA Talk: https://www.facebook.com/Syngapresearch/posts/pfbid08Aztex32vdwNZduVkPQeG353W49Dhq8iKJeZEkajKUmkeUiDdCwzyqa9ndEVpdCUl    To get these Therapies to kids the NHS data is key, ProMMis CHOP - Email them ENDD@chop.edu Stanford (Singed!) - https://curesyngap1.org/blog/srf-announces-stanford-launches-california-synaptopathy-clinic/ CHCO - https://curesyngap1.org/blog/visiting-syngap1-natural-history-study-childrens-hospital-colorado-chco/ Citizen Health https://cureSYNGAP1.org/Citizen is at 267, why not 300?   Hopkins article featuring SRF - Competition is good for the patient FB https://www.facebook.com/cureSYNGAP1/posts/pfbid07MP7St3zdxLKYXTJULKa5S35YvgL6AJndenHicedxU3rtQF6iY1wwwNUoDuUD9cpl LI https://www.linkedin.com/posts/curesyngap1_nih-cuts-stalling-progress-on-rare-genetic-activity-7328449817074946048-AAsB   ASGCT Mouse poster for Q504X from the JAX, Dr. Matt Simon Conf Video https://www.youtube.com/watch?v=loYXkkTSUIY  Presentation on AAV for SYNGAP1 at Allen by Dr. Megan Quinlan   What about this guy? Gift link: https://www.nytimes.com/2025/05/15/health/gene-editing-personalized-rare-disorders.html?unlocked_article_code=1.H08.E-oX.t5bo6kxJGUOU&smid=url-share  PBS: https://www.youtube.com/watch?v=dOeiPoa3gvM Eric Topol: https://erictopol.substack.com/p/the-first-human-to-undergo-in-vivo   More incredible news https://news.unl.edu/article/husker-team-wins-second-round-prize-in-nih-gene-editing-challenge   REPURPOSING Mike's post in private SRF Group: https://www.facebook.com/groups/syngap #Amlexanox with Fortuity Pharma. https://fortuitypharma.com/    Butyrate Update https://aesnet.org/abstractslisting/phenylbutyrate-for-syngap1-related-developmental-and-epileptic-encephalopathy Trial ending at year end, working with SLC6A1 and Rachel Heilmann to continue coverage, then we can scale, once we have a paper. SunButyrate https://a.co/d/7kiHXS8    PUBMED  328 total with 20 YTD https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&sort=date&sort_order=asc&timeline=expanded Sleep https://www.sciencedirect.com/science/article/abs/pii/S1389945724005793?via%3Dihub   SRF Fundraisers MDBR with AJH and HM https://curesyngap1.org/calendar/million-dollar-bike-ride-2025/   Well done to Tavilla and Jones!  We are over $221k Tavilla clears $160k for Sprint. https://donate.curesyngap1.org/campaign/sprint4syngap2025/c660255   Porter Jones and his friends William, Patrick, and Judson raised over $10k in doughnuts, this netted over $8k because people donated.  Amazing and thank you to Krispy Kreme.  https://donate.curesyngap1.org/event/sweets-for-syngap1/e678677   SRF PROFILES Vicky post in Mexico https://www.linkedin.com/posts/victoria-arteaga-26913433_diagnostico-epilepsia-syngap1-activity-7329725268003069953-R41P Vicky's Siblings Violeta and Lourdes, sisters to Amelia https://curesyngap1.org/syngap-siblings/ Harper Albrecht Wednesday Warrior #215 parents Ashley and Justin https://cureSYNGAP1.org/Warrior   PREREGISTER FOR THE CURE SYNGAP1 CONFERENCE https://curesyngap1.org/calendar/cure-syngap1-conference-2025-hosted-by-srf/

The San Jose Hockey Now Podcast is sponsored by Bring Hockey Back! It's part 2 of a mega-2025 Draft Lottery mailbag! Part 2 is all about what the San Jose Sharks should do with the 2025 No. 2 pick. In case you missed it, Part 1 focused on how to improve the Sharks next year, especially on defense. https://youtu.be/LJPWjFPxZUg Let's get to the questions! Jeremy: What would it take to trade up to the No. 1 pick? (2:16) Nick Valderrama: Who would Keegan replace Sheng with? Is there a trade for the San Jose Sharks' No. 2 that we like? Sam: Thoughts about Martone? (18:02) Brad Fitzpatrick: Is Martone a much more serious possibility than we think? Austin Dias: How interested are teams around the NHL in the No. 2 pick? Ben: What does the package look like that would tempt Mike Grier to trade down? Matt Harrison: Who should the Sharks dangle for defensive help? The No. 2 pick? Which prospects? Astoverpix: Trade Musty for defensive help? Dylan Smallwood: Would you make this No. 2 pick/Noah Dobson trade with the New York Islanders? (34:54) GH: No. 2 pick for Owen Power, Rasmus Dahlin, or Bowen Byram? David: Will the San Jose Sharks make any jersey changes this off-season? Arch Mickel: What's the plan for Sam Dickinson? Beast: Offer Mitch Marner a short-term, max AAV contract? (52:48) Lincoln Race: Pitch for Marner? Boomer: Sheng's hockey background? Juan Rebollo: Do the San Jose Sharks pick more for need in 2026? Zeke: How can you tell if Mike Grier is excited? Should the Sharks target Anthony Stolarz or Joseph Woll? SwedeShark: How likely is it that the Sharks pick Victor Eklund? Joseph: How hard will it be for the Sharks to fill their holes via free agency? Tgraveline: How chaotic will this off-season be league-wide? Chris: San Jose Sharks' roster construction/needs next year? (1:12:43) Just Steve: Which teams do you think that the Sharks are likely to leapfrog in the standings next year? Matthias893: Keegan's favorite book on his bookshelf? Sheng's personal favorite basketball player? Fin Coe: Thoughts on Leo Sahlin Wallenius? James Barrett: What's the most valuable surplus in the San Jose Sharks' system? rphillips19: Where would Michael Misa and Matthew Schaefer be picked if they were in the 2023 Draft, 2024 Draft? Have all successful rebuilds actually drafted their top defensemen? Stephanie k: Is William Eklund the Sharks' most valuable (reasonable) trade piece? (1:37:53) Kyle J from Australia: Where would Sam Dickinson be ranked in the 2025 Draft? Chaz Marshall: Who goes to wing, Michael Misa or Will Smith? Should Misa stay in juniors, go to the NCAA, or the NHL next year? Anthony: How about trading the Dallas Stars' first for defensive help? Shaun Abuzalaf: Offer sheet Fabian Zetterlund?

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

On this week's episode, we name and debate our Mount Rushmore for each position in the history of baseball. From there, we discuss the highest paid player (by AAV) at each spot on the diamond, the elimination of the buffer zone by umpires that has hitters and pitchers guessing the strike zone like never before, roster moves in Detroit, Texas, and Cincinnati, and which baseball players would be our top choices to enlist to be a part of our 100 player roster in a battle to the death against a gorilla.

In today's pod we break down the Cowboys future and in particular why it scares me. They are in a tough position to try to go from being a good team when healthy - to a great team. And it makes matters a lot more difficult when they are paying a quarterback an AAV of $60M per year along with a new head coach. I hope you enjoy! TWITTER: https://mobile.twitter.com/FBallAnalysisYT   DISCORD: https://discord.gg/XAjBEcGVbH   TIKTOK: https://vm.tiktok.com/ZMe5NbVa7/   Welcome to the Football Analysis Podcast! Subscribe for all NFL related content! Please drop 5 star rating if you enjoyed the pod as all support is very much appreciated! Thanks for listening!     #nfl #nflfootball #football #nfldraft #dallascowboys #cowboys    Support Us By Supporting Our Sponsors!   UNDERDOG Fantasy:  Up To $1,000 Bonus Cash When You Make Your First Deposit:  https://play.underdogfantasy.com/p-football-analysis     Gametime: Download the Gametime app (https://gametime.co/) and redeem code ANALYSIS for $20 off your first purchase (terms apply)

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena's AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena's XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube

Audio roundup of selected biopharma industry content from Scrip over the business week ended 28 February 2025. In this episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-4RXPQH4B5NBJ3AM7SFMPROUJ2U/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Fantasy Baseball Live – February 16 2025 @ 3 pm ETSegment 1 – News and Notes1.Alex Bregman finally signed with Boston for three years and $120 million. While it wasn't a lengthy deal, the AAV of $40 is tremendous. Of course, he can opt-out after each year.a.Let's examine the Boston Red Sox lineup to see what shakes out given that there is a strong possibility he plays second.2.Many thought the Padres were sellers, but they signed Nick Pivetta to a four-year, $55 million contract.a.He had a solid season in 2024 – 172 Ks in 142 IP with a 4.14 ERA. The data says there is more in the tank, and Petco will help with his flyball tendencies—what are your thoughts?Segment 2 – Outfield Preview1.How are you approaching this position for your upcoming drafts?2.We will break down the top 30 to 45 in detail. Then, go through 30 or so in less detail. We will end by jumping around the remaining ranked players.3.Which player not in the Top 10 has a chance to emerge there next season?4.Which Top 10 player will not be there next season?5.Give me a couple of sleepers6.Give me one, maybe two guys you are just going to avoid drafting?

Fantasy Baseball Live – February 16 2025 @ 3 pm ETSegment 1 – News and Notes1.Alex Bregman finally signed with Boston for three years and $120 million. While it wasn't a lengthy deal, the AAV of $40 is tremendous. Of course, he can opt-out after each year.a.Let's examine the Boston Red Sox lineup to see what shakes out given that there is a strong possibility he plays second.2.Many thought the Padres were sellers, but they signed Nick Pivetta to a four-year, $55 million contract.a.He had a solid season in 2024 – 172 Ks in 142 IP with a 4.14 ERA. The data says there is more in the tank, and Petco will help with his flyball tendencies—what are your thoughts?Segment 2 – Outfield Preview1.How are you approaching this position for your upcoming drafts?2.We will break down the top 30 to 45 in detail. Then, go through 30 or so in less detail. We will end by jumping around the remaining ranked players.3.Which player not in the Top 10 has a chance to emerge there next season?4.Which Top 10 player will not be there next season?5.Give me a couple of sleepers6.Give me one, maybe two guys you are just going to avoid drafting?

SEGMENT - After years of passiveness from Red Sox ownership, the Sox have agreed to a 3-year deal with 3B Alex Bregman carrying an AAV of $40 million. But Jones is skeptical to say that the Sox are fully back

Alex and Facci discuss Alex Len not signing with Indiana, and the Pacers bringing in Jahlil Okafor on a 10-day contract. Then, they answer Pt. 1 of the Mailbag Podcast. 1). Northeast Nightmare over on Blue Sky has 3 questions for us!  A). First, rank which opponent you'd like to see Indiana face in the first round out of Milwaukee, Detroit, Miami and Orlando. 1st by matchup, 2nd by storyline.  B). Do you think Myles Turner will credit the Pacers $10M towards his next contract since Indiana did him a service and paid him nearly $30M a year on the last renegotiation and extension?  C). Will the Pacers use Isaiah Jackson's disabled player exception to sign Alex Len? Is there any benefit towards that? (Mentioned James Johnson needing to be released, but this is why they traded Wiseman).  2). Aaron M — THE GOVERNOR of the Setting The Pace Fan Club  Do you think the best chance for the Pacers to win an NBA title is actually continuity, or is that just a word they throw around? This is considering the odds the Pacers win the #1 pick are zero like they appear to be.  3). Chuck and Jamie — THE OG FANS OF THE WEEK! At the halfway point: What has been your biggest surprise this season? Who has made the most improvements? Who/what has been the most disappointing? One thing you hope to see in the second half of the season? 4). Roosters — the President of the Setting The Pace Fan Club  In your estimations what are the chances Herb goes into the tax this offseason to sign Myles to a long term deal? Also, what would you be willing to sign him to if it were up to you? Personally I'd try to get him for 5/100 and offer him a NTC. Knowing may have to go higher AAV. Learn more about your ad choices. Visit podcastchoices.com/adchoices

James Anderson and seasoned NFBC Auction player Marc Winokur go through some recent high-stakes auctions and which players are more in-demand by auction players than by snake draft players! 00:00 Intro 01:20 Early Auctioning 13:10 Closers in Auctions 20:30 Buying Skubal 28:00 Old, boring SP2s 32:50 What A Cheap Offense Looks Like 38:00 Zero-Dollar Players 40:55 Stacking 46:00 Top Hitters Overpriced 50:00 AAV vs. ADP 54:20 Outfielders 01:02:30 Catchers 01:05:10 First Base 01:06:00 Second Base 01:13:30 Shortstop 01:17:35 Pitcher Learn more about your ad choices. Visit podcastchoices.com/adchoices

James Anderson and seasoned NFBC Auction player Marc Winokur go through some recent high-stakes auctions and which players are more in-demand by auction players than by snake draft players! 00:00 Intro 01:20 Early Auctioning 13:10 Closers in Auctions 20:30 Buying Skubal 28:00 Old, boring SP2s 32:50 What A Cheap Offense Looks Like 38:00 Zero-Dollar Players 40:55 Stacking 46:00 Top Hitters Overpriced 50:00 AAV vs. ADP 54:20 Outfielders 01:02:30 Catchers 01:05:10 First Base 01:06:00 Second Base 01:13:30 Shortstop 01:17:35 Pitcher Learn more about your ad choices. Visit podcastchoices.com/adchoices